• Neurocrine Biosciences presented new 2-year Phase 3 CAHtalyst Adult data for CRENESSITY (crinecerfont) at ENDO 2026.
• Trial follow-up showed sustained glucocorticoid dose reductions alongside improved cardiometabolic health, including weight-related outcomes and insulin resistance.
• Bone health measures trended favorably over long-term treatment, supporting a potential reduction in steroid-related skeletal risk.
• Patient survey results in the open-label extension indicated higher treatment satisfaction, improved quality of life, stronger confidence in managing classic CAH.
• Safety profile remained consistent through 2 years, with no new long-term safety signals reported.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150830PR_NEWS_USPR_____LA83033) on June 15, 2026, and is solely responsible for the information contained therein.